You just read:

Biosimilars Market Access in Psoriatic Arthritis 2017 - Payers are Unlikely to Implement Strong Incentives to Drive Uptake of Biosimilar Infliximab Due to Limited Use of the Drug - Research and Markets

News provided by

Research and Markets

May 18, 2017, 08:45 ET